Factor XI Inhibitors in Atrial Fibrillation: Insights and Implications from Recent Trials

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis Research

Background:

• Atrial fibrillation (AF) management prioritizes stroke prevention due to high thromboembolic risk.
• Direct oral anticoagulants (DOACs) are effective but carry bleeding risks and face significant undertreatment challenges in AF.
• Factor XI (FXI) inhibitors represent a novel therapeutic class aiming to balance efficacy and safety in anticoagulation.

Purpose of the Study:

• To review the current landscape of FXI inhibitors for stroke prevention in AF.
• To discuss the advantages, challenges, and potential applications of FXI inhibitors in anticoagulation therapy.
• To evaluate the evolving role of FXI inhibition in managing AF-related stroke risk.

Main Methods:

• Comprehensive review of published literature on FXI inhibitors in AF.
• Analysis of early and late-phase clinical trial data for FXI inhibitors.
• Comparative assessment of FXI inhibitors against DOACs regarding safety and efficacy.

Main Results:

• FXI inhibitors, including small molecules and monoclonal antibodies, show potential for reduced bleeding compared to DOACs.
• Early trials suggest favorable safety profiles for some FXI inhibitors like abelacimab.
• The OCEANIC-AF trial's early termination due to lack of efficacy with asundexian highlights concerns regarding FXI inhibition's effectiveness.

Conclusions:

• FXI inhibitors offer a promising alternative for stroke prevention in AF, particularly for patients at high bleeding risk.
• Uncertainty remains regarding the overall efficacy of the FXI inhibitor class, as evidenced by mixed clinical trial outcomes.
• Further Phase 3 trials are crucial to elucidate the true utility and optimal application of FXI inhibitors in AF anticoagulation.